Zhiqiang Meng
Fudan University Shanghai Cancer Center(CN)
Publications by Year
Research Areas
Hepatocellular Carcinoma Treatment and Prognosis, Pancreatic and Hepatic Oncology Research, Cholangiocarcinoma and Gallbladder Cancer Studies, Cancer, Hypoxia, and Metabolism, Cancer, Lipids, and Metabolism
Most-Cited Works
- → Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study(2021)1,051 cited
- → A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy(2016)666 cited
- → Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial(2020)632 cited
- → Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study(2023)612 cited
- → Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)(2023)404 cited
- → Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial(2021)391 cited
- → Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial(2023)380 cited
- → Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall‐cell lung cancer, or pancreatic cancer(2009)283 cited
- → Plasma extracellular vesicle long RNA profiling identifies a diagnostic signature for the detection of pancreatic ductal adenocarcinoma(2019)263 cited
- → MicroRNA 23b Regulates Autophagy Associated With Radioresistance of Pancreatic Cancer Cells(2013)239 cited